Where Are They Now · Profile 05

Rick Bright

Rick Bright

Former director of the Biomedical Advanced Research and Development Authority (BARDA), whose agency requested the March 2020 hospital-only hydroxychloroquine emergency use authorization — and who then became a whistleblower after he was removed.

Claims are labeled Documented, Allegation, Open question or Gap (something the public record does not yet show). An allegation or open question is not a finding of wrongdoing. The film calls his conduct “sabotage”; that is the film’s argument. Bright has not been charged with or found liable for any wrongdoing, and the one formal finding in his file — by the U.S. Office of Special Counsel in 2020 — went in his favor. On several points below, the paper trail cuts against the film.

Who he was in the COVID era

  • Director of BARDA and HHS Deputy Assistant Secretary for Preparedness and Response from November 2016 until he was removed on April 21, 2020 and moved to a narrower NIH role. He joined BARDA in 2010. Documented (his own sworn written testimony) Source: Bright written testimony, House Energy & Commerce Health Subcommittee (May 14, 2020)
  • BARDA requested the hydroxychloroquine/chloroquine EUA. FDA’s March 28, 2020 Emergency Use Authorization letter is addressed to “Dr. Rick Bright, Ph.D., Director, BARDA,” and answers his request. It covered drug from the Strategic National Stockpile for certain hospitalized patients (adults and adolescents of at least 50 kg) when a clinical trial was not available or feasible. Documented Source: FDA EUA letter of authorization, Mar. 28, 2020 (copy posted by Washoe County)
  • Filed a whistleblower complaint with the U.S. Office of Special Counsel on May 5, 2020, alleging he was removed for resisting politically connected contracts and the push to “flood” communities with hydroxychloroquine. He testified to the House Energy & Commerce Health Subcommittee, chaired by Rep. Anna Eshoo, on May 14, 2020. Documented Sources: Katz Banks Kumin (his lawyers); PBS NewsHour
  • Resigned from government on Oct. 6, 2020. Named to the Biden-Harris Transition COVID-19 Advisory Board on Nov. 9, 2020 — the same board as Ezekiel Emanuel. Documented Sources: UCSB American Presidency Project; Wikipedia summary

In the film

  • Bright is the central figure of chapters 25–32 (01:07:07–01:23:55). Clips include “I wish I’d never heard of hydroxychloroquine, honestly” (01:09:34), hearing exchanges with Reps. Eshoo, Engel, Ruiz, Burgess and Bucshon (01:10:26–01:19:01), and “Had nothing to do with politics, sir” (01:18:00 / 01:19:01). Documented (what the film shows)
  • Narration at 01:09:49 says Bright, his team and FDA members “sabotaged efforts to release hydroxychloroquine.” Allegation (the film’s argument; see the record below)
  • The film (01:19:24–01:20:11), citing Bright’s own complaint, says that on March 24, 2020 Janet Woodcock urged BARDA to seek an EUA instead of a national expanded-access IND, and that Bright called the EUA a compromise to “rein in” HHS leadership’s plan to make the drug available outside hospitals. The quote comes from his complaint. Documented (quote) The film’s inference that this was meant to “deny early treatment” is its argument. Allegation (intent)
  • Full timecodes are in the annotated transcript.

COVID-era money

Whistleblower settlement with HHS

  • HHS settled Bright’s retaliation complaint; OSC announced the settlement on Aug. 9, 2021. His lawyer said he “has been compensated to the fullest extent allowed by the law” and “will receive back pay and compensatory damages.” CNN reported the settlement covered lost salary, benefits and pension contributions. Documented Sources: OSC (Aug. 9, 2021); Reuters; KVIA/CNN
  • The dollar amount of the settlement has not been disclosed. Gap

Rockefeller Foundation — Pandemic Prevention Institute

  • Hired by the Rockefeller Foundation in early 2021 as senior vice president and chief of its Pandemic Prevention Institute. He left in September 2022, when the institute was folded back into the foundation instead of being spun out. Documented Source: Bloomberg (Sept. 27, 2022)
  • The foundation’s 2022 Form 990-PF lists “Rick Arthur Bright, SVP/Chief – Pandemic Prev. Inst.” with $1,111,131 in compensation and $43,969 in benefit and deferred-compensation contributions — the fourth-highest among the officers and key employees listed, in the year he left. Documented (IRS filing) Sources: Rockefeller Foundation 2022 990-PF (Part VII); ProPublica Nonprofit Explorer
  • The 2022 figure may include separation pay; the return does not say. His 2021 compensation is not shown in ProPublica’s extract. Open question

The film’s money claim

  • The film (01:37:44–01:38:02) says Bright’s leaked emails show BARDA “wanted more money before they would assist,” and that Congress then gave BARDA billions that went to companies such as AstraZeneca. Allegation (the film’s reading of the emails) BARDA’s 2020 awards were agency spending, not personal income; we found no evidence that Bright personally profited from any BARDA award.

Consequences

  • No adverse legal or professional consequence found. He has not been charged, sanctioned or found liable. Documented (absence of a record, as of October 2026)
  • Before the settlement, OSC found “reasonable grounds” to believe HHS retaliated against him (May 2020). HHS under the Trump administration denied wrongdoing. Documented Source: The Hill
  • His separate OSC disclosure complaint — alleging HHS wrongdoing and contracts “without scientific merit” — was still under investigation in August 2021. We have not found the outcome. Gap
  • Timeline note: the June 15, 2020 request to revoke the hydroxychloroquine EUA came from BARDA under Gary L. Disbrow, not Bright, who had been removed on April 21. Bright’s role was the March request to issue the hospital-only EUA. Documented Sources: FDA revocation letter to Disbrow (Jun. 15, 2020); FDA press release
  • FOIA trail: America First Legal sued HHS (D.D.C. 1:23-cv-03680) for records of Woodcock, Bright, Disbrow and Hinton mentioning hydroxychloroquine, early treatment or remdesivir. HHS made interim releases through at least May 14, 2025. Those records could confirm or undercut the film’s account of the Woodcock–Bright exchange; we have not yet reviewed them. Open question Sources: HHS litigation releases (America First Legal); 14th interim response (May 14, 2025)

Where is he now

  • Founder and CEO of Bright Global Health since November 2022, a pandemic-preparedness consulting and advisory firm, according to his profiles. No revenue or client list is public. Documented (self-reported) Sources: LinkedIn; XPRIZE profile
  • Advisory board member at Parallel Bio, announced June 16, 2026, where he is listed as “CEO of Bright Global Health and former Director of BARDA.” Documented Source: Business Wire (Jun. 16, 2026)
  • Member of the inaugural Scientific Advisory Council of the Fund for Science and Technology (February 2026). Documented (his LinkedIn post resharing the announcement) Source: LinkedIn (Feb. 2026)

What the record does not show yet

  • The dollar amount of the HHS whistleblower settlement. Gap
  • His 2021 Rockefeller Foundation compensation, and whether the 2022 figure includes severance. Gap
  • His federal salary as BARDA director, 2016–2020. Gap
  • Pay for his advisory roles and Bright Global Health’s revenue and clients. Gap
  • The outcome of the OSC disclosure-unit investigation. Gap
  • What the America First Legal FOIA releases show about Bright–Woodcock hydroxychloroquine communications in March–April 2020. Gap

Last reviewed October 2026. This profile is updated as new records surface. Corrections: Press@EpidemicOfFraud.com

← All profiles